

Curriculum Vitae

Sonja Loges Professor, Dr. med., Dr. rer. nat.
d.o.b. December 14th, 1973, in Paderborn, Germany

University Education

2014 Board Certification in Internal Medicine, Hematology and Oncology
2012 Assistant Professor (Habilitation)
2005 MD Award (Dr. med.), University Medical Center Hamburg
2004 PhD Award in Biochemistry and Molecular Biology (Dr. rer. nat.), University of Hamburg,
Department of Biology
2004 Medical Examination (Approbation)
2000-2004 PhD Studies, University of Hamburg, Department of Biology
1998-2004 Medical School, University Medical Center Hamburg
1998 Master Award in Biochemistry and Molecular Biology, University of Hamburg,
Department of Biochemistry
1993-1998 Bachelor & Master Studies in Biochemistry and Molecular Biology, University of

Scientific Career

2021- Scientific director of the Mannheim Cancer Center (MCC), Mannheim, Germany
2020- Director of DKFZ-Hector Cancer Institute and Chair of Department for Personalized
Oncology, University Medical Center Mannheim, University of Heidelberg, Mannheim,
Germany
2020- Head of the Division of Personalized Medical Oncology, DKFZ, Heidelberg
2016-2020 W3 Heisenberg Professor, Department of Hematology and Oncology, University Medical
Center Hamburg
2015-2020 Leader of Thoracic Oncology and Personalized Oncology Programs, Department of
Hematology and Oncology, University Medical Center Hamburg
2015-2020 Attending Physician and Group Leader, Department of Hematology and Oncology &
Institute of Tumor Biology, University Medical Center Hamburg
2011-2017 Max Eder Group Leader, Department of Hematology and Oncology & Institute of Tumor
Biology, University Medical Center Hamburg
2010-2014 Resident, Department of Hematology and Oncology, University Medical Center Hamburg
2007-2010 Post-Doctoral Researcher, Vesalius Research Center, VIB-KU Leuven, Leuven, Belgium
(Mentor: Prof. Peter Carmeliet)
2005-2007 Resident, Department of Hematology and Oncology, University Medical Center Hamburg

Awards and Honors

2019 Call ('Ruf') to W3 DKTK professorship „Signaling-based Precision Oncology“, Charité Berlin
(declined)
2018-2024 ERC Starting Grant ELIMINATE (European Research Council)
2016-2020 Heisenberg-Professorship (German Research Council)
2010 -2017 Max-Eder Group Leader Program (German Cancer Aid)
2015 Call ('Ruf') to W3 professorship “Clinical and Experimental Leukemia Research” at the
University of Münster (declined)
2015 Research Price (Hamburg Cancer Society)
2014 Ludolph-Brauer Price (Northwestern German Society for Internal Medicine)
2011 Price for Research and Innovation (German Society for Hematology and Oncology)
2009-2010 Postdoctoral Fellowship (Flemish Science Foundation)
2007-2009 Mildred-Scheel Postdoctoral Fellowship (German Cancer Aid)
2002 Roling Predoctoral Fellowship (Roling Foundation)
1999-2001 Werner-Otto Predoctoral Fellowship (Werner-Otto Foundation)

Citation Record

Total citations: 76,454; h-index:130; h-index since 2017: 68 (Google Scholar July 20th, 2022)

Top-10 selected Publications

Loges S, Heuser M, Chromik J, Sutamtewagul G, Kapp-Schwoerer S, Crugnola M, Di Renzo N, Lemoli R, Mattei D, Fiedler W, Alvarado-Valero Y, Ben-Batalla I, Waizenegger J, Rieckmann LM, Janning M, Collienne M, Imbusch CD, Beumer N, Micklem D, Nilsson LH, Madeleine N, McCracken N, Oliva C, Gorcea-Carson C, Gjertsen BT. Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial. **Nat Commun** 2025; 16(1):2846 doi: [10.1038/s41467-025-58179-6](https://doi.org/10.1038/s41467-025-58179-6).

Rieckmann LM, Spohn M, Ruff L, Agorku D, Becker L, Borchers A, Krause J, O'Reilly R, Hille J, Velthaus-Rusik JL, Beumer N, Günther A, Willnow L, Imbusch CD, Iglauer P, Simon R, Franzenburg S, Winter H, Thomas M, Bokemeyer C, Gagliani N, Krebs CF, Sprick M, Hardt O, Riethdorf S, Trumpp A, Stoecklein NH, Peine S, Rosenstiel P, Pantel K, **Loges S**, Janning M. Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells. **Mol Cancer** 2024; 23(1):93 doi: [10.1186/s12943-024-01984-2](https://doi.org/10.1186/s12943-024-01984-2).

Engelmann J, Zarrer J, Gensch V, Riecken K, Berenbrok N, Luu TV, Beitzten-Heineke A, Vargas-Delgado ME, Pantel K, Bokemeyer C, Bhamidipati S, Darwish IS, Masuda E, Burstyn-Cohen T, Alberto EJ, Ghosh S, Rothlin C, Hesse E, Taipaleenmäki H, Ben-Batalla I, **Loges S**. Regulation of bone homeostasis by MERTK and TYRO3. **Nat Commun** 2022; 13(1):7689 doi: [10.1038/s41467-022-33938-x](https://doi.org/10.1038/s41467-022-33938-x).

Janning M, Süptitz J, Albers-Leischner C, Delpy P, Tufman A, Velthaus-Rusik JL, Reck M, Jung A, Kauffmann-Guerrero D, Bonzheim I, Brändlein S, Hummel HD, Wiesweg M, Schildhaus HU, Stratmann JA, Sebastian M, Alt J, Buth J, Esposito I, Berger J, Tögel L, Saalfeld FC, Wermke M, Merkelbach-Bruse S, Hillmer AM, Klauschen F, Bokemeyer C, Büttner R, Wolf J, **Loges S**. National Network Genomic Medicine Lung Cancer (nNGM). Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). **Ann Oncol** 2022; 33(6):602-615 doi: [10.1016/j.annonc.2022.02.225](https://doi.org/10.1016/j.annonc.2022.02.225).

Westphalen BC, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert W, Zips D, **Loges S**. Working Group Molecular Diagnostics and Therapy. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group "Molecular Diagnostics and Therapy". **Eur J Cancer** 2020; 135:1-7 doi: [10.1016/j.ejca.2020.04.019](https://doi.org/10.1016/j.ejca.2020.04.019).

Wroblewski M, Bauer R, Cubas Córdova M, Udonta F, Ben-Batalla I, Legler K, Hauser C, Egberts J, Janning M, Velthaus J, Schulze C, Pantel K, Bokemeyer C, **Loges S**. Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B. **Nat Commun** 2017; 8(1):269 doi: [10.1038/s41467-017-00327-8](https://doi.org/10.1038/s41467-017-00327-8).

Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, **Loges S**. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. **Blood** 2013; 122(14):2443-2452 doi: [10.1182/blood-2013-03-491431](https://doi.org/10.1182/blood-2013-03-491431).

Schmidt T, Kharabi Masouleh B, **Loges S**, Cauwenberghs S, Fraisl P, Maes C, Jonckx B, De Keersmaecker K, Kleppe M, Tjwa M, Schenk T, Vinckier S, Fragoso R, De Mol M, Beel K, Dias S, Verfaillie C, Clark RE, Brümmendorf TH, Vandenberghhe P, Rafii S, Holyoake T, Hochhaus A, Cools J, Karin M, Carmeliet G,

Dewerchin M, Carmeliet P. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. **Cancer Cell** 2011; 19(6):740-753 doi: [10.1016/j.ccr.2011.05.007](https://doi.org/10.1016/j.ccr.2011.05.007).

Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. **Cancer Cell** 2009; 15(3):167-170 doi: [10.1016/j.ccr.2009.02.007](https://doi.org/10.1016/j.ccr.2009.02.007).

Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, Fischer U, Gehling UM, Schuch G, Hossfeld DK, Fiedler W. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. **J Clin Oncol** 2005; 23(6):1109-1117 doi: [10.1200/JCO.2005.05.058](https://doi.org/10.1200/JCO.2005.05.058).